{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:40:20Z","timestamp":1789663220354,"version":"4.0.1"},"reference-count":89,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP19K16938"],"award-info":[{"award-number":["JP19K16938"]}]},{"name":"JSPS KAKENHI","award":["JP17K08953"],"award-info":[{"award-number":["JP17K08953"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer activity but often causes severe peripheral neuropathy. Although bortezomib-induced peripheral neuropathy (BIPN) is a dose-limiting toxicity, there are no recommended therapeutics for its prevention or treatment. One of the most critical problems is a lack of knowledge about pathological mechanisms of BIPN. Here, we summarize the known mechanisms of BIPN based on preclinical evidence, including morphological abnormalities, involvement of non-neuronal cells, oxidative stress, and alterations of transcriptional programs in both the peripheral and central nervous systems. Moreover, we describe the necessity of advancing studies that identify the potential efficacy of approved drugs on the basis of pathological mechanisms, as this is a convincing strategy for rapid translation to patients with cancer and BIPN.<\/jats:p>","DOI":"10.3390\/ijms22020888","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T05:17:34Z","timestamp":1610947054000},"page":"888","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy"],"prefix":"10.3390","volume":"22","author":[{"given":"Shota","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo 162-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3673-6824","authenticated-orcid":false,"given":"Nobuaki","family":"Egashira","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade\u00ae: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: An update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Coluzzi, F., Rolke, R., and Mercadante, S. (2019). Pain Management in Patients with Multiple Myeloma: An Update. Cancers, 11.","DOI":"10.3390\/cancers11122037"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: Part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Salat","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2015.11.006","article-title":"Drug Repurposing for the Development of Novel Analgesics","volume":"37","author":"Sisignano","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur. J. Pain."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1158\/0008-5472.CAN-12-4370","article-title":"Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade","volume":"73","author":"Trevisan","year":"2013","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1111\/bph.14063","article-title":"Characterization of a rat model of bortezomib-induced painful neuropathy","volume":"174","author":"Duggett","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1254\/jphs.13274FP","article-title":"Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice","volume":"124","author":"Kitamura","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brainres.2014.06.013","article-title":"Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy","volume":"1574","author":"Robinson","year":"2014","journal-title":"Brain Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Carozzi, V.A., Renn, C.L., Bardini, M., Fazio, G., Chiorazzi, A., Meregalli, C., Oggioni, N., Shanks, K., Quartu, M., and Serra, M.P. (2013). Bortezomib-induced painful peripheral neuropathy: An electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072995"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.expneurol.2010.09.004","article-title":"Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies","volume":"226","author":"Carozzi","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/glia.21065","article-title":"Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy","volume":"58","author":"Shin","year":"2010","journal-title":"Glia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.expneurol.2013.12.020","article-title":"Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model","volume":"253","author":"Ale","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Geisler, S., Doan, R.A., Cheng, G.C., Cetinkaya-Fisgin, A., Huang, S.X., Hoke, A., Milbrandt, J., and DiAntonio, A. (2019). Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight, 4.","DOI":"10.1172\/jci.insight.129920"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"146621","DOI":"10.1016\/j.brainres.2019.146621","article-title":"Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy","volume":"1730","author":"Bechakra","year":"2020","journal-title":"Brain Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10072-010-0475-2","article-title":"Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: An immunofluorescence study","volume":"32","author":"Giannoccaro","year":"2011","journal-title":"Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12974-018-1270-x","article-title":"High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats","volume":"15","author":"Meregalli","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-019-1461-0","article-title":"Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy","volume":"16","author":"Moschetti","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuroscience.2014.05.051","article-title":"Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat","volume":"274","author":"Robinson","year":"2014","journal-title":"Neuroscience"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jphs.2018.06.008","article-title":"Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro","volume":"137","author":"Kawashiri","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events","volume":"17","author":"Anderl","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuro.2013.09.001","article-title":"Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons","volume":"39","author":"Staff","year":"2013","journal-title":"Neurotoxicology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Moschetti, G., Kalpachidou, T., Amodeo, G., Lattanzi, R., Sacerdote, P., Kress, M., and Franchi, S. (2020). Prokineticin Receptor Inhibition With PC1 Protects Mouse Primary Sensory Neurons From Neurotoxic Effects of Chemotherapeutic Drugs in vitro. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02119"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2015.12.038","article-title":"Neurotoxicity to DRG neurons varies between rodent strains treated with cisplatin and bortezomib","volume":"362","author":"Podratz","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.scr.2017.06.006","article-title":"Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy","volume":"22","author":"Wing","year":"2017","journal-title":"Stem Cell Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Ale","year":"2015","journal-title":"Neurotox. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.pain.2013.07.032","article-title":"Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase","volume":"154","author":"Janes","year":"2013","journal-title":"Pain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1111\/bph.13129","article-title":"The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives","volume":"172","author":"Nassini","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bph.13652","article-title":"The peptide Ph\u03b11\u03b2, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice","volume":"174","author":"Tonello","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1159\/000495828","article-title":"Blocking TRPA1 and TNF-\u03b1 Signal Improves Bortezomib-Induced Neuropathic Pain","volume":"51","author":"Li","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.33549\/physiolres.934015","article-title":"Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib","volume":"68","author":"Liu","year":"2019","journal-title":"Physiol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Takayama, Y., Derouiche, S., Maruyama, K., and Tominaga, M. (2019). Emerging Perspectives on Pain Management by Modulation of TRP Channels and ANO1. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143411"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/pr.110.002725","article-title":"International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family","volume":"62","author":"Wu","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101502","DOI":"10.1016\/j.redox.2020.101502","article-title":"Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib","volume":"32","author":"Jannuzzi","year":"2020","journal-title":"Redox Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16318","DOI":"10.1038\/s41598-018-34507-3","article-title":"Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib","volume":"8","author":"Karademir","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbi.2015.11.004","article-title":"Upregulation of CCL2 via ATF3\/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy","volume":"53","author":"Liu","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbi.2014.01.020","article-title":"TNF-alpha-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy","volume":"38","author":"Zhang","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Guo, Y., Xu, X., Huang, J., Wang, Z., Li, Z., and Liu, Z. (2020). The Actions and Mechanisms of P2X7R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/8143754"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2016.05.004","article-title":"Inhibition of the neuronal NF\u03baB pathway attenuates bortezomib-induced neuropathy in a mouse model","volume":"55","author":"Ale","year":"2016","journal-title":"Neurotoxicology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2018.01.011","article-title":"Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib","volume":"302","author":"Liu","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuropharm.2014.08.004","article-title":"Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat","volume":"86","author":"Ghelardini","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2014.11.009","article-title":"Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy","volume":"285","author":"Robinson","year":"2015","journal-title":"Neuroscience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.neuropharm.2017.06.027","article-title":"Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord","volume":"123","author":"Xie","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_59","first-page":"1239","article-title":"Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1\/2 activation","volume":"8","author":"Tsubaki","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00540-015-2077-x","article-title":"The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia: The role of TNF-\u03b1 and IL-1\u03b2","volume":"30","author":"Li","year":"2016","journal-title":"J. Anesth."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tsubaki, M., Takeda, T., Matsumoto, M., Kato, N., Yasuhara, S., Koumoto, Y.I., Imano, M., Satou, T., and Nishida, S. (2018). Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C\/extracellular signal-regulated kinase pathway. Tumor Biol., 40.","DOI":"10.1177\/1010428318808670"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000491662","article-title":"Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib","volume":"48","author":"Duan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12974-018-1327-x","article-title":"Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib","volume":"15","author":"Chen","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Sun, Y., Yang, Y., Zhang, S., Xu, T., Xin, W., Wu, S., and Zhang, X. (2019). GATA3-dependent epigenetic upregulation of CCL21 is involved in the development of neuropathic pain induced by bortezomib. Mol. Pain, 15.","DOI":"10.1177\/1744806919863292"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.279.5356.1552","article-title":"Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1","volume":"279","author":"Lee","year":"1998","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2018.12.003","article-title":"Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"413","author":"Tomita","year":"2019","journal-title":"Toxicology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jphs.2015.09.004","article-title":"Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: Possible involvement of kappa opioid receptor","volume":"129","author":"Higuchi","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14287","DOI":"10.1038\/s41598-020-71138-z","article-title":"Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro","volume":"10","author":"Takacs","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1248\/bpb.b17-00243","article-title":"Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy","volume":"40","author":"Nakagawa","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-pharmtox-010617-052832","article-title":"TRP Channels as Potential Drug Targets","volume":"58","author":"Moran","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay, I., Kulkarni, A., and Khairatkar-Joshi, N. (2016). Blocking TRPA1 in Respiratory Disorders: Does It Hold a Promise?. Pharmaceuticals, 9.","DOI":"10.3390\/ph9040070"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/j.pain.0000000000001697","article-title":"Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents","volume":"161","author":"Stockstill","year":"2020","journal-title":"Pain"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mao-Ying, Q.L., Kavelaars, A., Krukowski, K., Huo, X.J., Zhou, W., Price, T.J., Cleeland, C., and Heijnen, C.J. (2014). The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100701"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ludman, T., and Melemedjian, O.K. (2019). Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy. Mol. Pain., 15.","DOI":"10.1177\/1744806919850043"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1038\/ncomms12840","article-title":"Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS","volume":"7","author":"Miyake","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00384-018-3104-9","article-title":"Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: Randomized, controlled study","volume":"33","author":"Ibrahim","year":"2018","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Bouchenaki, H., Danigo, A., Sturtz, F., Hajj, R., Magy, L., and Demiot, C. (2020). An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models. Fundam. Clin. Pharmacol.","DOI":"10.1111\/fcp.12617"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cavaletti, G., and Marmiroli, P. (2020). Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers, 12.","DOI":"10.3390\/cancers12061370"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"LoCoco, P.M., Risinger, A.L., Smith, H.R., Chavera, T.S., Berg, K.A., and Clarke, W.P. (2017). Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. Elife, 6.","DOI":"10.7554\/eLife.29626"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/j.pain.0000000000000862","article-title":"Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats","volume":"158","author":"Hamity","year":"2017","journal-title":"Pain"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Huang, K.M., Leblanc, A.F., Uddin, M.E., Kim, J.Y., Chen, M., Eisenmann, E.D., Gibson, A., Li, Y., Hong, K.W., and DiGiacomo, D. (2020). Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J. Clin. Invest., 130.","DOI":"10.1172\/JCI136796"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Stage, T.B., Hu, S., Sparreboom, A., and Kroetz, D.L. (2020). Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. Clin. Transl. Sci.","DOI":"10.1111\/cts.12915"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/cas.14178","article-title":"Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma","volume":"110","author":"Maekawa","year":"2019","journal-title":"Cancer Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/888\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:12:12Z","timestamp":1760159532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":89,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020888"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020888","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,17]]}}}